Neurophysiology of the Basal Ganglia, Thalamus, and Cerebellum in Patients With Movement Disorders

NCT06848530 | Recruiting

• 1 other identifier: 857558
• Study Type: interventional
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

The research study is being conducted to better understand parts of the human brain called the cortex, basal ganglia, thalamus, and cerebellum in patients with movement disorders (such as Parkinson's disease, essential tremor, dystonia, or ataxia). These brain structures are involved in movement disorders. This study attempts to better understand the brain electrical activity associated with these disorders, both in patients with and without deep brain stimulation (DBS). Recordings are made from the scalp with a noninvasive electrode and/or through the DBS stimulator if the participant has a stimulator model that is able to sense brain activity. These recordings are analyzed along with measures of movement disorder symptoms to identify brain signal signatures of symptoms.

Conditions

Movement Disorders

Outcome Measures

Primary Outcomes (1)

• Neural signal biomarkers

  Spatiotemporal patterns of brain neural activity (neural signal biomarkers / neurophysiologic signatures) associated with movement disorders symptoms.

  5 years

Study Arms (2)

Participants without Deep Brain Stimulators

EXPERIMENTAL

Multimodal neurophysiology (for example, electroencephalography and electromyography) will be measured during the following: Movement disorder medication administration -The patient's movement disorders medications, prescribed by their treating physicians outside of this study, may be administered during an experimental session.

Other: Prescribed Medications

Participants with Deep Brain Stimulators

EXPERIMENTAL

Multimodal neurophysiology (for example, electroencephalography and electromyography) will be measured during the following: Movement disorder medication administration -The patient's movement disorders medications, prescribed by their treating physicians outside of this study, may be administered during an experimental session. Deep brain stimulator (DBS) adjustment - Participants who have had deep brain stimulation implantation as part of their standard-of-care clinical treatment may participate in this study. The patient's stimulator may be adjusted within normal clinical limits during an experimental session.

Other: Prescribed Medications; Other: Deep brain stimulation adjustment

Interventions

Prescribed Medications OTHER

participant's movement disorders medications, prescribed by their treating physician

Participants with Deep Brain Stimulators; Participants without Deep Brain Stimulators

Deep brain stimulation adjustment OTHER

Deep brain stimulator parameters may be adjusted within normal clinical limits

Participants with Deep Brain Stimulators

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients 18 years of age and above
• Any patient who has been diagnosed by a movement disorders neurologist with one of the following movement disorders:
• Parkinson's disease
• Dystonia
• Tremor, including essential tremor
• Cerebellar ataxia
• Other hyperkinetic movement disorders, such as chorea and tics

You may not qualify if:

• \- Patients with dementia

Sponsors & Collaborators

• University of Pennsylvania: lead

Study Sites (1)

Pennsylvania Hospital

Philadelphia, Pennsylvania, 19107, United States

RECRUITING

MeSH Terms

Conditions

Movement Disorders

Condition Hierarchy (Ancestors)

Central Nervous System Diseases; Nervous System Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Professor of Neurology

Study Record Dates

• First Submitted: February 21, 2025
• First Posted: February 27, 2025
• Study Start: December 10, 2025
• Primary Completion (Estimated): April 1, 2030
• Study Completion (Estimated): April 1, 2030
• Last Updated: March 11, 2026

Record last verified: 2026-03

Locations

US (1)